| Document |
Document Title |
|
WO/2016/135749A1 |
This invention also relates to novel class of diosgenin acetate-Isoxazole and the synthesis of diosgenin acetate-Isoxazole starting from Diosgenin and its relatives with five (5) synthetic routes, acetylation (A), F-ring opening of diosg...
|
|
WO/2016/079517A1 |
The invention relates to compounds of formula (I), wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
|
|
WO/2016/039359A1 |
The present invention relates to: a terpenoid derivative which is capable of activating a Keap1/Nrf2/ARE signaling pathway and has an excellent anti-inflammatory activity and an excellent cell-protecting activity; and a sustained-release...
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2015/198232A1 |
The present invention discloses fused triterpene compounds, represented by the compounds of Formula I (as described herein), processes for their preparation, pharmaceutical compositions comprising the said compounds, their use as retinoi...
|
|
WO/2015/158163A1 |
The present invention relates to cyclopentanoperhydrophenanthrene framework compounds and a preparation method therefor. The compounds have certain biological activity, can also be used as an intermediate synthon for synthesizing some co...
|
|
WO/2015/158216A1 |
Disclosed is the use of Kudinosides for the manufacture of treating pulmonary disease. And kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (...
|
|
WO/2015/095971A1 |
The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): (Formula (I)) (A) in combination with an aminoglycoside antibiotic for preventing or treating a bacterial infection in a subject; or (B) ...
|
|
WO/2015/081778A1 |
The present invention belongs to the field of organic synthesis, relates to a method for synthesizing a saponin, and in particular, to a method for constructing a glycosidic bond in a saponin, and comprises the following steps: directly ...
|
|
WO/2015/075549A1 |
A Salacia composition described herein significantly reduces appetite, activates Hormone Sensitive Lipase, and manages a healthy lipid profile through inhibition of HMG-CoA Reductase enzyme. Salacia compositions described herein include ...
|
|
WO/2015/075693A1 |
The invention relates to a process for the synthesis of (11 β,17α)-17-acetoxy-11 - inethyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.
|
|
WO/2015/077780A1 |
Provided herein are synthetic analogs of withanolide natural products of formula (I), wherein R1-R4 are as defined herein, and their pharmaceutical uses in treating neurodegenerative diseases.
|
|
WO/2015/048316A1 |
The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compoun...
|
|
WO/2015/023593A1 |
This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic...
|
|
WO/2014/207309A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or preve...
|
|
WO/2014/207310A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2to R7are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevent...
|
|
WO/2014/184271A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1 is a hydroxy group and R2, R3, R4, R5, and R6 are as described herein. The present inven...
|
|
WO/2014/117710A1 |
Lanosterol derivatives useful as anti-cancer agent, which can inhibit the growth of lung cancer cells, liver cancer cells, mammary cancer cells, brain cancer cells and pancreatic cancer cells, possibly by acting on the RHO pathway. These...
|
|
WO/2014/107231A1 |
The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) ther...
|
|
WO/2014/104905A1 |
Process for preparation of 3,24;16,22-di-O,O-isopropylideneprotoescigenin comprises acetonidation of protoescigenin monohydrate in the mixture consisting of 0 - 100% vol. of acetone and 100 - 0% vol. of 2,2-dimethoxypropane, in presence ...
|
|
WO/2014/040837A1 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2013/185613A1 |
The present invention belongs to the field of natural medicine and pharmaceutical chemistry. Provided are novel derivatives of paridis saponins I with 5'-acylated arabinofuranosyl group, or pharmaceutically acceptable salts thereof. Also...
|
|
WO/2013/188818A1 |
Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles ...
|
|
WO/2013/173862A1 |
The present invention provides an improved synthesis of a class of steroid saponins. Furthermore, the present invention provides a method of selectively discriminating between the C2 and C3 hydroxyl groups of a mono-glycosylated steroid ...
|
|
WO/2013/170761A1 |
Disclosed is a method for preparing a pregnane derivative 16,17-acetal (ketal) compound shown in the general formula I, the method comprising the step of reacting a compound of a general formula II with a compound of a general formula II...
|
|
WO/2013/169647A1 |
The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods f...
|
|
WO/2013/149580A1 |
Provided herein are timosaponin compounds of Frmula I, II, IIΙ, I', II' and IIΙ', pharmaceutical compositions comprising the coumpounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for pre...
|
|
WO/2013/124395A1 |
The invention relates to a process for preparing ciclesonide in epimerically pure form, a corticosteroid of formula 1: Ciclesonide is used for the treatment of respiratory complaints.
|
|
WO/2013/113294A1 |
Disclosed in the present invention are a sterol derivative, preparation method therefor and use thereof. Said sterol derivative comprises sterol compounds having structure according to formula (I), or pharmaceutically acceptable salts of...
|
|
WO/2013/097835A1 |
The present invention relates to the fields of chemistry and pharmaceuticals and, in particular, to obtaining novel molecular entities — steroid derivatives — that affect the central nervous system. Diosgenin, which is a natural sapo...
|
|
WO/2013/097665A1 |
A saponin derivative, the structure thereof is as represented by formula (I). Animal experimentation proves that the saponin derivative is provided with significant antidepressant pharmacological activity, can be used as an active ingred...
|
|
WO/2013/097681A1 |
The present invention relates to the field of pharmaceutical chemicals, and provides a sterols derivative, and a preparation method and purpose thereof. Specifically, the present invention relates to a compound shown in formula I, or pha...
|
|
WO/2013/036674A1 |
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R5 are as defined and described herein, compositions thereof, and methods of using the same.
|
|
WO/2013/036679A1 |
The present invention provides compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Rx is as defined and described herein, compositions thereof, and methods of using the same.
|
|
WO/2013/019711A2 |
The invention is directed to novel 17β-heteroaryl substituted steroids of Formula I, pharmaceutical compositions thereof, and their use as modulators of GABAA receptors.
|
|
WO/2013/017374A1 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2013/016725A1 |
Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
|
|
WO/2012/123493A9 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprisingthem, combinations and therapeutic uses the...
|
|
WO/2012/170573A2 |
The invention provides epoxytaccalonolide microtubule stabilizers and their use as anti-proliferative microtubule stabilizing agents.
|
|
WO/2012/157130A1 |
The invention provides a method for differentiating an adenoma using the 18-oxoF present in the peripheral blood of a primary aldosteronism patient. Moreover, the invention provides a method and compound for determination of the 18-oxoF ...
|
|
WO/2012/123482A2 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2012/115026A1 |
The purpose of the present invention is to provide a composition for preventing or treating dyslipidemia and a disease related thereto such as hypercholesterolemia or hypertriglyceridemia, and one or more members selected from among a dr...
|
|
WO/2012/109752A1 |
The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular o...
|
|
WO/2012/106393A2 |
The present invention features novel withanolides, as well as analogs and salts thereof, for use in the treatment of proliferative disease, cardiovascular disease, neurodegenerative disease and inflammatory disease.
|
|
WO/2012/079275A1 |
Provided is a method for preparing fluticasone furoate (fluoromethyl 6α,9α-difluoro-11β-hydroxy-16a-methyl-17α-[(2-furoyl)oxy
]-3-one androsta-1,4-diene-17β-thiocarboxylate) represented by Formula I. The method comprises: 1) forming...
|
|
WO/2012/002536A1 |
Disclosed is a VEGF production promoter, an agent for improving the nature of hair, or an external preparation for the skin, which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food or ...
|
|
WO/2011/153719A1 |
Smilaxchinoside F compound and its separating method are disclosed. The compound has the structure as following. The use of smilaxchinoside F in the manufacture of a medicine for treating abnormal angiogenesis and its relating diseases i...
|
|
WO/2011/140375A1 |
The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form compr...
|
|
WO/2011/134954A1 |
A compound of general formula (I ), wherein R1-R17 and the ------ line take various meanings for use in the treatment of cancer.
|
|
WO/2011/095535A2 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
